financetom
Business
financetom
/
Business
/
Marzetti Q1 revenue up 5.8%, beats analyst expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marzetti Q1 revenue up 5.8%, beats analyst expectations
Nov 4, 2025 5:06 AM

Overview

* Marzetti ( MZTI ) Q1 revenue grows 5.8% yr/yr, beating analyst expectations

* Adjusted operating income for Q1 rises 8.1%, reflecting higher gross profit

* Restructuring charges related to facility closure reduced Q1 net income

Outlook

* Marzetti ( MZTI ) anticipates Retail sales growth from licensing program and proprietary brands

* Foodservice sales expected to be supported by quick-service restaurant demand

Result Drivers

* RETAIL SEGMENT - Sales growth driven by New York Bakery frozen garlic bread and licensing programs

* FOODSERVICE SEGMENT - Higher demand from national chain restaurant accounts and inflationary pricing drove sales growth

* COST SAVINGS - Adjusted gross margin improved due to ongoing cost savings programs and higher sales volumes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Sales Beat $493.47 $474.11

mln mln (6

Analysts

)

Q1 EPS $1.71

Q1 Net $47.18

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the food processing peer group is "buy."

* Wall Street's median 12-month price target for Marzetti Co ( MZTI ) is $190.00, about 16.7% above its November 3 closing price of $158.24

* The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mynaric Secures Third $5 Million Bridge Loan for 'Immediate' Working Capital Purposes; Shares Jump Premarket
Mynaric Secures Third $5 Million Bridge Loan for 'Immediate' Working Capital Purposes; Shares Jump Premarket
Dec 24, 2024
05:00 AM EST, 12/24/2024 (MT Newswires) -- Mynaric AG ( MYNA ) disclosed Monday it secured a $5 million loan following an amendment to its loan agreement with US-based lenders. The company expected to have the third bridge loan fully drawn as of Dec. 23 to meet immediate working capital needs. The third loan is in addition to the $95...
Update: NeueHealth Shares Soar Premarket Following $1.3 Billion Deal to Go Private With New Enterprise Associates
Update: NeueHealth Shares Soar Premarket Following $1.3 Billion Deal to Go Private With New Enterprise Associates
Dec 24, 2024
05:07 AM EST, 12/24/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) NeueHealth's ( NEUE ) shares soared more than 60% in premarket activity on Tuesday after the company said overnight it agreed to be acquired and taken private by an affiliate of New Enterprise Associates for an enterprise value of about $1.3...
Russian cargo ship sinks in Mediterranean after explosion, Russian Foreign Ministry says
Russian cargo ship sinks in Mediterranean after explosion, Russian Foreign Ministry says
Dec 24, 2024
* Ship was en route to Vladivostok, says owner * Was reported to be carrying port cranes, ice-breaker parts * 14 crew rescued, two still missing * Cause of engine room explosion unknown so far (Adds Russian embassy to Spain in paragraph 4, entities sanctioned status in paragraph 5) By Andrew Osborn and Gleb Stolyarov MOSCOW, Dec 24 (Reuters) -...
Abbott Laboratories, DexCom Settle Patent Disputes Related to Continuous Glucose Monitoring Products
Abbott Laboratories, DexCom Settle Patent Disputes Related to Continuous Glucose Monitoring Products
Dec 24, 2024
05:10 AM EST, 12/24/2024 (MT Newswires) -- Abbott Laboratories ( ABT ) said Monday it has reached a settlement with DexCom ( DXCM ) to resolve all outstanding patent disputes related to continuous glucose monitoring products. The details of the settlement remain confidential but Abbott said there are no financial payments involved in the agreement. Abbott also said the settlement...
Copyright 2023-2026 - www.financetom.com All Rights Reserved